Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Andarine
Also known as: S-4, GTx-007
Andarine was one of the first SARMs developed by GTx Inc. It showed promise for muscle wasting and osteoporosis in preclinical trials but development was halted due to visual side effects.
Risk Level
Medium RiskDifficulty
Intermediate| CAS Number | 401900-40-1 |
| Molecular Formula | C19H18F3N3O6 |
| Class | SARM |
| Category | SARMs |
Mechanism of Action
Andarine binds androgen receptors with partial agonist activity. It has strong anabolic effects on muscle and bone with reduced androgenic activity. Its partial agonist nature means it can also act as an antagonist in some tissues.
Dosing Research
Preclinical studies used various doses. Research community references 25-50 mg/day, often split into multiple doses. Half-life approximately 4-6 hours. Cycles typically 8 weeks.
Side Effects & Risks
Unique visual disturbances including yellow tint and difficulty adjusting to darkness, caused by binding to retinal receptors. Reversible upon discontinuation. Testosterone suppression at higher doses.
Research Studies
Related compounds
Ostarine
SARMOstarine is the most widely studied SARM, originally developed for muscle wasting and osteoporosis. It has completed multiple Phase II and Phase III clinical trials, making it one of the few SARMs with substantial human data.
Ligandrol
SARMLigandrol is a non-steroidal SARM developed by Ligand Pharmaceuticals for muscle wasting conditions. It demonstrated significant lean mass gains in Phase I trials at doses as low as 1 mg/day.
Cardarine
OtherCardarine is not actually a SARM but a PPARδ agonist, often grouped with SARMs commercially. It was developed by GlaxoSmithKline for metabolic and cardiovascular diseases but was abandoned due to cancer findings in rodent studies.
RAD-140
SARMRAD-140 is a potent non-steroidal SARM developed by Radius Health. It has shown neuroprotective properties in preclinical studies and is currently in early clinical trials for breast cancer.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.